1. Home
  2. CALC vs PYPD Comparison

CALC vs PYPD Comparison

Compare CALC & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • PYPD
  • Stock Information
  • Founded
  • CALC 2011
  • PYPD 2008
  • Country
  • CALC United States
  • PYPD Israel
  • Employees
  • CALC N/A
  • PYPD N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • PYPD Medical/Dental Instruments
  • Sector
  • CALC Health Care
  • PYPD Health Care
  • Exchange
  • CALC Nasdaq
  • PYPD Nasdaq
  • Market Cap
  • CALC 22.9M
  • PYPD 36.0M
  • IPO Year
  • CALC N/A
  • PYPD 2020
  • Fundamental
  • Price
  • CALC $1.64
  • PYPD $3.50
  • Analyst Decision
  • CALC Strong Buy
  • PYPD Strong Buy
  • Analyst Count
  • CALC 3
  • PYPD 5
  • Target Price
  • CALC $16.33
  • PYPD $11.40
  • AVG Volume (30 Days)
  • CALC 28.9K
  • PYPD 1.4M
  • Earning Date
  • CALC 08-11-2025
  • PYPD 08-13-2025
  • Dividend Yield
  • CALC N/A
  • PYPD N/A
  • EPS Growth
  • CALC N/A
  • PYPD N/A
  • EPS
  • CALC N/A
  • PYPD N/A
  • Revenue
  • CALC N/A
  • PYPD N/A
  • Revenue This Year
  • CALC N/A
  • PYPD N/A
  • Revenue Next Year
  • CALC N/A
  • PYPD N/A
  • P/E Ratio
  • CALC N/A
  • PYPD N/A
  • Revenue Growth
  • CALC N/A
  • PYPD N/A
  • 52 Week Low
  • CALC $1.42
  • PYPD $2.30
  • 52 Week High
  • CALC $5.97
  • PYPD $4.42
  • Technical
  • Relative Strength Index (RSI)
  • CALC 49.89
  • PYPD 55.70
  • Support Level
  • CALC $1.59
  • PYPD $3.34
  • Resistance Level
  • CALC $1.69
  • PYPD $3.57
  • Average True Range (ATR)
  • CALC 0.15
  • PYPD 0.16
  • MACD
  • CALC 0.01
  • PYPD -0.04
  • Stochastic Oscillator
  • CALC 52.26
  • PYPD 60.51

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: